Tag: Adjuvant Patient Program for Melanoma

FDA approved BMS’s Yervoy
October 29, 2015 Off

FDA approved BMS’s Yervoy

By Dino Mustafić

U.S. Food and Drug Administration (FDA) has approved BMS’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomy.